BC99 Clinical Research——Sports Nutrition

As of February 2026, more than 1,000 subjectsacross all age groups-including children, adults, andthe elderly-have been enrolled in clinical trialsinvolving BC99. Among the clinical interventionregimens, the maximum daily dosage administeredwas 48 billion CFU, with the longest interventionduration lasting up to 12 weeks.No serious adverse events (SAEs) associated withBC99 were reported in any dosage group or agesubgroup throughout the entire clinical trial period.No abnormal alterations were observed in laboratorytest parameters (covering complete blood count,hepatic and renal function tests, etc.), vital signs, orroutine physical examinations.Collectively, these robust findings verify that BC99possesses an excellent safety and tolerance inhumans.

BC99 Promotes Protein Digestion and Metabolism in Active Individuals

Following  BC99  intervention,muscle  mass  was  significantly  augmented  and  exercise-induced  muscle  damage  was  mitigated  in physically  active  individuals.BC99  intervention  markedly  upregulated  the  expression  of  BCAAs,including  leucine,alongside

elevated  levels  of  testosterone  and  glucagon-like   peptide-1(GLP-1).These  findings  demonstrate  that   BC99   not  only   promotes increases in muscle mass but also facilitates robust protein digestion and metabolic turnover